PF-Atlas › Clinical Trials › NCT05515627

Atezolizumab for Idiopathic Pulmonary Fibrosis

Atezolizumab · Phase 1

Registry ID

NCT05515627

Phase

Phase 1

Status

Active, not recruiting

Drug / intervention

Atezolizumab

Sponsor

Cedars-Sinai Medical Center

Start

2023-02-15

Enrollment

Locations

About this trial

The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).

View NCT05515627 on ClinicalTrials.gov →

Explore related

All Atezolizumab trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05515627 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.